Search | Page 22 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Resistance to Hypomethylating Agents in the Treatment of MDS

    ... with the commonly used hypomethylating agents (HMA), azacitidine (Vidaza®), and decitabine (Dacogen®)? The ... the mechanisms of action is for the two HMA drugs.  Both 5-azacitidine and deoxy-azacitdine are thought to cause reversal of DNA ...

    Interview last updated 06/17/2014 - 9:15am.

  2. Aplastic Anemia and MDS Overlap Syndrome

    ... the standard of care should be hypomethylating agents, azacitidine (Vidaza®) and decitabine (Dacogen®), which of course ...

    Interview last updated 05/13/2015 - 8:37am.

  3. ASH 2012 - Reviewing MDS Progress from Research and Clinical Perspectives

    ... and applied it specifically to patients who were on azacitidine (Vidaza®). This is important because both the IPSS and IPSS-R ... be used to predict survival in patients who are treated with azacitidine, thus it is valid for a patient who is about to start azacitidine ...

    Interview last updated 02/07/2013 - 1:28pm.

  4. MDS and MDS/MPN: Past, Present, and Future 2014 American Society of Hematology (ASH) Satellite Symposium Summary for Patients and Families

    ... protein formation). The hypomethylating agents (HMAs) azacitidine (Vidaza®) and decitabine (Dacogen®) inhibit DNA ...

    Page last updated 03/13/2015 - 5:00pm.

  5. Interviews with the Experts Comorbidities: When Other Medical Conditions Affect MDS Treatment

    ... low blood counts that often occur when treatment with azacitidine (Vidaza®) is started, there could be serious complications, ... even more difficult to treat with standard therapies such as azacitidine (Vidaza®) or lenalidomide (Revlimid®). The more things that are ...

    Interview last updated 11/17/2014 - 9:31am.

  6. Clinical Trial Basics

    ... (Revlimid) eculizumab (Soliris) azacitidine (Vidaza) eltrombopag (Promacta) Research has also ...

    Page last updated 01/20/2015 - 4:58pm.

  7. Clinical Trial Basics

    ... (Revlimid) eculizumab (Soliris) azacitidine (Vidaza) eltrombopag (Promacta) Research has also ...

    Page last updated 01/20/2015 - 4:46pm.

  8. Interviews with the Experts Managing MDS With Supportive Care and Active Treatment

    ... agents, which are the two FDA-approved drugs azacitidine (Vidaza®) anddecitabine (Dacogen®). These are the primary ...

    Interview last updated 09/22/2014 - 12:25pm.

  9. Treating Higher-Risk Myelodysplastic Syndromes

    ... cell transplant, may be hypomethylating agents like azacitidine (Vidaza®) or decitabine (Dacogen®). If patients have ... The current standard of care treatments for MDS includes azacitidine, decitabine, or lenalidomide (Revlimid®). ...

    Interview last updated 05/18/2012 - 1:55pm.

  10. Understanding Prognosis in MDS

    ... (Revlimid®) and the hypomethylating agents—azacitidine (Vidaza®) and decitabine (Dacogen®)—and IPSS doesn’t ...

    Interview last updated 05/02/2012 - 4:36pm.